
Opinion|Videos|April 18, 2025
Important Updates in the Management of Uncomplicated UTIs
Panelists discuss how American Urological Association (AUA) guidelines for recurrent uncomplicated urinary tract infections (UTIs) in women recommend culture-confirmed diagnosis, prophylactic antibiotics, nonantibiotic prevention, self-initiated treatment, and behavioral modifications while noting pivmecillinam’s recent FDA approval. Pivmecillinam features a penicillin-binding protein 2 inhibition mechanism with 85% to 95% efficacy against gram-negative uropathogens, including extended-spectrum β-lactamase producers; minimal intestinal flora disruption; low resistance rates; and primarily mild gastrointestinal adverse effects.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Summarize the current AUA guideline recommendations in managing recurrent uncomplicated UTIs in women.
- Pivmecillinam was recently FDA approved in April 2024. Briefly describe the mechanism of action of pivmecillinam and its clinical efficacy and safety profile.
Advertisement
Related to this article

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.

A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Follitropin Delta Achieves Ongoing Pregnancy in 64% Under Age 35
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5


